

Antibacterial Susceptibility Patterns and Cross-Resistance of *Acinetobacter*, Isolated from Hospitalized Patients, Southern Iran

S Japoni¹, S Farshad², A Abdi Ali¹, A Japoni^{2*}

¹Department of Biology, Alzahra University, Tehran, ²Professor Alborzi Clinical Microbiology Research Center, Nemazee hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: *Acinetobacter* is a multi-drug resistant and nosocomial pathogen. The aim of this study was to determine antibacterial susceptibility patterns and cross-resistance of *Acinetobacter* species.

Methods: This study was conducted in Nemazee Hospital, Shiraz, Iran from October 2007 to September 2008. Species identification was carried out by API E20. Minimum inhibitory concentration and cross-resistance of the isolated strains to 12 antibiotics were determined by E-test method.

Results: Eighty eight isolates of *Acinetobacter* were collected from patients' samples. *Acinetobacter baumannii* was isolated most frequently (79; 89.8%). Colistin, imipenem and meropenem were found to be the three most effective antibiotics with 97.7%, 77.3% and 72.7% activity against the isolates, respectively. Multi-drug resistance was revealed among 2 to 11 antibiotics and high cross-resistance was also noticed.

Conclusion: To alleviate the situation, strict control measures and appropriate effective antibiotic therapy should be adopted to reduce hospital costs and related mortality.

Keywords: *Acinetobacter*; Antibiotic resistance; Cross resistance; Iran

Introduction

Acinetobacter is a gram-negative, strictly aerobic, non-motile, non-fermentative, oxidase negative, catalase positive and citrate positive bacterium. Most strains can grow in a simple mineral medium containing single carbon and energy source.¹ *Acinetobacter baumannii* is more frequent in clinical samples, while *A. lwoffii* and *A. haemolyticus* were also isolated in environmental settings. Infections due to *A. baumannii* are frequently found in the intensive care units (ICUs), where they are implicated as the cause of ventilator-associated pneumonia (VAP), urinary tract infections, and bacteremia. In clinical practices, *Acinetobacter* infections are influenced by various

risk-factors including the use of medical devices such as endotracheal tubes, intravascular and urinary catheters, the exposure to broad-spectrum antibiotics and the ICU wards where the patients are admitted and the infection rate is high.² Resistance rates to fluoroquinolones, aminoglycosides, cephalosporins, and penicillins are high in several regions. Although carbapenem remains mainstay of the therapy for suspected *Acinetobacter* infections, resistance to this antimicrobial class has been increasingly reported. Thus, therapeutic options can become markedly limited.^{3,4}

Major hospital outbreaks, related to multi-drug resistant (MDR) *Acinetobacter spp.* have been recently described in several countries, making surveillance of antimicrobial susceptibility an important public health task.⁵ This study was conducted to assess the prevalence of different *Acinetobacter* species and their corresponding frequencies in samples. Furthermore, susceptibility patterns and cross-resistance of *Acinetobacter* to different antibiotics were determined.

*Correspondence: Aziz Japoni, PhD, Professor Alborzi Clinical Microbiology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. Tel: +98-711-6474264, Fax: +98-711-6474303, e-mail: japonia@hotmail.com

Received: March 22, 2011

Accepted: July 25, 2011

Materials and Methods

This study was a cross-sectional one in which bacteria identification was carried out by standard biochemical tests; API E20 (BioMerieux, Marcy I Etoile, France), in Nemazee Hospital, Shiraz, Iran from October 2007 to September 2008. Briefly, the isolates which were mostly obtained from blood, urine wound and sputum, were sub-cultured on blood agar and MacConkey agar to ensure viability and purity. The isolates were stored at -20°C in nutrient broth containing 50% v/v glycerol. Minimum inhibitory concentration (MIC) of the isolates to 12 antibiotics including ciprofloxacin, colistin, ceftazidime, imipenem, ampicillin/sulbactam, meropenem, gentamicin, norfloxacin, amikacin, cefepime, tobramycin and cefoperazon/sulbactom were determined by E-test method and interpreted as recommended by the manufacturer's instruction. Cross-resistance of antibiotic resistant isolates to different antibiotics was also evaluated.

The data were analyzed statistically by SPSS software version 15 (SPSS, Chicago, IL, USA). Cross-resistance was obtained by cross tabulation of the resistant samples within SPSS software.

Results

Eighty eight isolates of *Acinetobacter* were obtained. *Acinetobacter spp.* was isolated predominantly from

men (70%), as compared to women (30%). The samples consist of; 35 (39.8%) blood, 15 (17%) wound, 15 (17%) sputum, 13 (14.8 %) urine and 10 (11.4%) samples of CSF, eyes and joints. *Acinetobacter baumannii* strains were isolated most frequently (79; 89.8%), followed by *A. lwoffii* (8; 9.1%) and *A. haemolyticus* (1; 1.1%).

Based on the susceptibility of the isolated *Acinetobacter* to the 12 antibiotics, colistin, imipenem and meropenem proved to be the three most effective antibiotics with 97.7%, 77.3% and 72.7% activities against the isolates, respectively. These data were collected in Table 1. Comparison of MICs for the two main isolated species revealed that *A. baumannii spp.* was more resistant, compared to *A. lwoffii* (Table 1). *Acinetobacter baumannii* was resistant between 2 to 11 antibiotics of which resistance rates of 6, 7 and 8 antibiotics were observed predominantly (Table 2). To more precisely determine the resistance patterns of *A. baumannii* to the tested antibiotics, cross-resistance of the isolates was calculated and presented in Table 3. High cross-resistance was noticed to the majority of the tested antibiotics.

Discussion

Various biochemical and molecular methods to identify *Acinetobacter* have been applied. According to these methods, these bacteria are categorized into

Table 1: In vitro susceptibility patterns of 88 *Acinetobacter spp.* to 12 antibiotics and comparison of susceptibility values for *A. baumannii* and *A. lwoffii*.

Antibiotics	Total <i>Acinetobacter spp.</i> No. 88		<i>A. baumannii</i> No. 79		<i>A. lwoffii</i> No. 8	
	R (%)	S (%)	R (%)	S (%)	R (%)	S (%)
PM	71 (80.7)	17 (19.3)	70 (88.6)	9 (11.4)	0 (0)	8 (100)
TZ	72 (81.8)	16 (18.2)	69 (87.3)	10 (12.6)	2 (25)	6 (75)
GM	70 (79.5)	18 (20.5)	69 (87.3)	10 (12.6)	0 (0)	8 (100)
NX	67 (76.1)	21 (23.9)	67 (84.8)	12 (15.2)	0 (0)	8 (100)
AK	66 (75)	22 (25)	65 (82.3)	14 (17.7)	1 (12.5)	7 (87.5)
CI	65 (73.9)	23 (26.1)	65 (82.3)	14 (17.7)	0 (0)	8 (100)
TM	32 (36.4)	56 (63.6)	31 (39.2)	48 (60.7)	0 (0)	8 (100)
CPS	29 (33)	59 (67)	29 (36.7)	50 (63.3)	0 (0)	8 (100)
AB	34 (38.6)	54 (61.4)	22 (27.8)	57 (72.1)	1 (12.5)	7 (87.5)
MP	24 (27.2)	64 (72.7)	22 (27.8)	57 (72.1)	0 (0)	8 (100)
IP	20 (22.7)	68 (77.3)	18 (22.8)	61 (77.2)	1 (12.5)	7 (87.5)
CO	2 (2.3)	86 (97.7)	1 (1.3)	78 (98.7)	0 (0)	8 (100)

Abbreviations: TZ, ceftazidime; GM, gentamicin; NX, norfloxacin; AK, amikacin; CI, ciprofloxacin; TM, tobramycin; CPS, cefoperazon/sulbactom AB, ampicillin/sulbactam; MP, meropenem; IP, imipenem; CO, colistin; R, resistant; S, sensitive.

Table 2: Frequencies and patterns of multi-resistant isolates of *Acinetobacter* to the tested antibiotics.

Resistant antibiotics	Antibiotic resistance pattern	No.	Total
0	Sensitive	12	12
1	TZ	1	1
2	TZ-AK	1	4
	AB-PM	1	
	AK-TM	1	
	GM-TM	1	
3	AB-IP-MP	1	1
5	NX-TZ-GM-TM-PM	1	2
	TZ-GM-AK-TM-PM	1	
6	NX-TZ-GM-CI-AK-PM	13	17
	NX-TZ-GM-CI-AB-PM	2	
	NX-TZ-GM-AK-TM-PM	1	
	NX-TZ-CI-AK-MP-PM	1	
7	NX-TZ-GM-CI-AK-CPS-PM	2	17
	NX-TZ-GM-CI-AK-TM-PM	14	
	NX-TZ-GM-CI-AK-PM-CO	1	
8	NX-TZ-GM-AK-IP-TM-MP-PM	1	18
	NX-TZ-GM-CI-AB-AK-CPS-PM	11	
	NX-TZ-GM-CI-AK-TM-MP-PM	2	
	NX-TZ-GM-CI-AB-AK-TM-PM	1	
	TZ-GM-AB-IP-TM-MP-PM-CO	1	
	TZ-GM-CI-AK-IP-TM-MP-PM	1	
	NX-TZ-GM-CI-AB-AK-TM-MP	1	
9	NX-TZ-GM-CI-AB-IP-CPS-MP-PM	2	2
10	NX-TZ-GM-CI-AB-AK-IP-CPS-MP-PM	6	6
11	NX-TZ-GM-CI-AB-AK-IP-TM-CPS-MP-PM	8	8
Total	26 (patterns)	88	88

Abbreviations: CI, ciprofloxacin; CO, colistin; TZ, ceftazidime; AB, ampicillin/sulbactam; IP, imipenem; MP, meropenem; GM, gentamicin; NX, norfloxacin; AK, amikacin; PM, cefepime; TM, tobramycin; CPS, ceftoperazone/sulbactam

several genomic groups, but only a few have received genomic names.⁶⁻⁸ In this study, 89.8% of the isolates were *A. baumannii* and 10.2% were non-*A. baumannii* (9.1% *A. lwoffii* and 1.1% *A. haemolyticus*). Based on a study by Feizabadi *et al.* in Tehran, 84.4% of the samples were *A. baumannii* and 15.6% were non-*A. baumannii*.⁹ Similar to the current results, Seifert *et al.* reported that 72.9% of the clinical specimens were *A. baumannii* and the rest were non-*A. baumannii*.¹⁰ Most samples in the present study were isolated from the blood (39.8%) and the rest were isolated from wound, sputum, urine and other sites. In Feizabadi *et al.* report, blood samples were more frequent (37.7%). Predomination of *Acinetobacter* from blood samples may indicate the role of bloodstream in disseminating the infection.¹¹

In the present study, *A. baumannii* with high resistance to different classes of antibiotics including

fluoroquinolones, aminoglycosides and cephalosporins were detected. In agreement with this survey, multi-drug resistant *Acinetobacter* was isolated from the hospitalized patients worldwide.¹²⁻¹⁷ Nevertheless, *A. lwoffii* expressed low resistance to the most of tested antibiotics. Low resistance of *A. lwoffii* could be due to the absence of efficient antibiotic resistance capturing system (integron) or as a result of its low dissemination in hospital environment. It has been proven that *A. baumannii* has infected prolonged hospitalized patients.^{18,19} *Acinetobacter spp.* was highly sensitive to colistin (97.7%) and moderately sensitive to imipenem (77.3%) and meropenem (72.7%). Despite the high sensitivity of *Acinetobacter* to colistin, its use should be restricted to life-threatening conditions because of serious neurological and renal side effects.^{20,21}

Table 3: Cross-resistance of *Acinetobacter* to the tested antibiotics.

	No.	Number of isolates and percent (value in parenthesis) resistant to											
		NX	TZ	GM	CI	AB	AK	IP	TM	CPS	MP	PM	CO
NX	67		67 (100)	66 (98.5)	64 (95.5)	31 (46.3)	62 (92.5)	17 (25.4)	27 (40.3)	29 (43.3)	21 (31.3)	67 (100)	1 (1.5)
TZ	72	67 (93.1)		69 (95.8)	65 (90.3)	32 (44.4)	65 (90.3)	19 (26.4)	30 (41.7)	29 (40.3)	23 (31.9)	70 (97.2)	2 (2.8)
GM	70	66 (94.3)	69 (98.6)		64 (91.4)	32 (45.7)	63 (90)	19 (27.1)	31 (44.3)	29 (41.4)	22 (31.4)	69 (98.6)	2 (2.9)
CI	65	64 (98.5)	65 (100)	64 (98.5)		31 (47.7)	61 (93.8)	17 (26.2)	25 (38.5)	29 (44.6)	21 (32.3)	65 (100)	1 (1.5)
AB	34	31 (91.2)	32 (94.2)	32 (94.2)	31 (91.2)		27 (79.4)	18 (52.9)	10 (29.4)	27 (79.4)	19 (55.9)	33 (97.1)	1 (2.9)
AK	66	62 (93.9)	65 (98.5)	63 (95.4)	61 (92.4)	27 (40.9)		16 (24.2)	29 (43.9)	27 (40.9)	20 (30.3)	64 (96.9)	1 (1.5)
IP	20	17 (85)	19 (95)	19 (95)	17 (85)	18 (90)	16 (84.2)		10 (50)	16 (84.2)	20 (100)	19 (95)	1 (5)
TM	32	27 (84.4)	30 (93.7)	31 (96.9)	25 (78.1)	10 (31.2)	29 (90.6)	10 (31.2)		7 (21.9)	13 (40.6)	30 (93.7)	1 (3.1)
CPS	29	29 (100)	29 (100)	29 (100)	29 (100)	27 (93.1)	27 (93.1)	16 (55.2)	7 (24.1)		16 (55.2)	29 (100)	0 (0)
MP	24	21 (87.5)	23 (95.8)	22 (91.7)	21 (87.5)	19 (79.2)	20 (83.3)	20 (83.3)	13 (54.2)	16 (66.7)		23 (95.8)	1 (4.2)
PM	71	67 (94.4)	70 (98.6)	69 (97.2)	65 (91.5)	33 (46.5)	64 (90.1)	19 (26.8)	30 (42.2)	29 (40.8)	23 (32.4)		2 (2.8)
CO	2	1 (50)	2 (100)	2 (100)	1 (50)	1 (50)	1 (50)	1 (50)	1 (50)	0 (0)	1 (50)	2 (100)	

Abbreviations: NX, norfloxacin; TZ, ceftazidime ; GM, gentamicin ;CI, ciprofloxacin; AB, ampicillin/sulbactam ;AK, amikacin; IP, imipenem; TM, tobramycin ; CPS, cefoperazon/sulbactom ; MP, meropenem;PM, cefepime; CO, colistin.

The high antibiotic resistance observed in the present study, could be due to the extensive clinical administration of antibiotics. Acquisition of antibiotic resistance in *Acinetobacter* is a result of transferable resistance elements such as plasmid, integron and transposon.²² Of the mentioned factors, integron has received more attention in developing antibiotic resistance due to high efficient capturing system.²²⁻²⁵ To alleviate the situation, periodical determination of the regional antibiotic susceptibility patterns of *Acinetobacter* is recommended. Furthermore, strict control measures and appropriate effective antibiotic therapy should be adopted. The majority of the isolated *Acinetobacter* exhibited cross-resistance to the tested antibiotics (Table 3), and consequently limited the application of effective antibiotics, in cases empiric therapy needs to be considered or alternative therapy has indication. Determination of the source of infection in the hospitals using Pulse Field Gel Electrophoresis (PFGE) and constant training of the medical staff to control the infection are also recommended

and could be helpful.

In conclusion, due to the high possibility of transmission of the antibiotic resistance through a variety of transmissible elements such as plasmid, transposon and specially integron, reduction in the prevalence of multi-drug resistant bacteria in clinics and hospitals is mandatory. By taking comprehensive control measures and making rational prescription of appropriate antibiotics, the situation could be improved accordingly to an acceptable level.

Acknowledgement

Deep thanks are due to Prof. A. Alborzi for his invaluable help with provision of the lab. facilities in Prof. Alborzi Clinical Microbiology Research Center. Our gratitude to Hassan Khajehei, PhD for his linguistic copy editing.

Conflict of interest: None declared.

References

- 1 Dijkshoorn L, van Aken E, Shunburne L, van der Reijden TJ, Bernards AT, Nemeč A, Towner KJ. Prevalence of *Acinetobacter baumannii* and other *Acinetobacter* spp. in faecal samples from non-hospitalized individuals. *Clin Microbiol Infect* 2005;**11**: 329-32. [15760432] [<http://dx.doi.org/10.1111/j.1469-0691.2005.01093.x>]
- 2 Agodi A, Zarrilli R, Barchitta M, Anzaldi A, Di Popolo A, Mattaliano A, Ghiraldi E, Trivali S. Alert surveillance of intensive care unit acquired *Acinetobacter* infections in a Sicilian hospital. *Clin Microbiol Infect* 2006;**12**:241-7. [16451411] [<http://dx.doi.org/10.1111/j.1469-0691.2005.01339.x>]
- 3 Mahgoub S, Ahmed J, Glatt AE. Completely resistant *Acinetobacter baumannii* strains. *Infect Control Hosp Epidemiol* 2002;**23**:477-9. [12186218] [<http://dx.doi.org/10.1086/502091>]
- 4 Levin AS. Multi-resistant *Acinetobacter* infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. *Clin Microbiol Infect* 2002;**8**:144-53. [12010169] [<http://dx.doi.org/10.1016/j.1469-0691.2002.00415.x>]
- 5 Villegas MV, Hartstein AI. *Acinetobacter* outbreaks, 1977-2000. *Infect Control Hosp Epidemiol* 2003;**24**: 284-95. [12725359] [<http://dx.doi.org/10.1086/502205>]
- 6 Baumann P. Isolation of *Acinetobacter* from soil and water. *J Bacteriol* 1968;**96**:39-42.
- 7 Bouvet PJM, Grimond PAD. Taxonomy of the genus *Acinetobacter* with the recognition of *Acinetobacter Baumannii* sp. nov., *Acinetobacter haemolyticus* sp. nov., *Acinetobacter Johnsonii* sp. nov. and emended description of *Acinetobacter calcoaceticus* and *Acinetobacter Iwoffii*. *Int J Syst Bacteriol* 1986;**36**:228-40. [<http://dx.doi.org/10.1099/00207713-36-2-228>]
- 8 Johnson JL, Anderson RS, Ordal EJ. Nucleic acid homologies, among oxidase- negative moraxella species. *J Bacteriol* 1970;**101**:568-73. [541 3826]
- 9 Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, Soroush S, Mohammadi-Yegane S. Antimicrobial susceptibility patterns and distribution of bla_{OXA} genes among *Acinetobacter* Spp. isolated from patients at Tehran hospitals. *Jpn J Infect Dis* 2008;**61**:274-8.[18653968]
- 10 Seifert H, Baginski R, Schulze A, Pulverer G. The distribution of *Acinetobacter* species in clinical culture materials. *Zentralbl Bakteriol* 1993;**279**:544-52. [8305812]
- 11 Gisneou JM, Rodriguez-Bano J. Nosocomial bacteremia due to *Acinetobacter baumannii*: epidemiology, clinical features and treatment. *Clin Microbiol Infect* 2002;**8**:687-93. [12445005] [<http://dx.doi.org/10.1016/j.1469-0691.2002.00487.x>]
- 12 Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and Colistin: review of available interpretative criteria and quality control guidelines. *J Clin Microbiol* 2001;**39**:183-90. [11136 768] [<http://dx.doi.org/10.1128/JCM.39.1.183-190.2001>]
- 13 Davis KA, Moran KA, McAllister K, Gray PJ. Multi-drug resistant *Acinetobacter* extremity infections in soldiers. *Emerg Infect Dis* 2005;**11**: 1218-24. [16102310]
- 14 Katsaragakis S, Markogiannakis A, Toutouzias KG, Drimousis P, Larentzakis A, Theodoraki, EM, Theodorou D. *Acinetobacter baumannii* infections in a surgical intensive care unit: predictors of multi-drug resistance. *World J Surg* 2008;**32**: 1194-202. [18408967] [<http://dx.doi.org/10.1007/s00268-008-9571-3>]
- 15 Reynolds R, Potz N, Colman M, Williams A, Livermore D, Macgowan A. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteremia Resistance surveillance programme. *J Antimicrob Chemother* 2004;**53**:1018-32. [15128723] [<http://dx.doi.org/10.1093/jac/dkh232>]
- 16 Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from SENTRY antimicrobial surveillance program (North America, 2001). *Int J Antimicrob Agents* 2004;**24**:111-8. [15288308] [<http://dx.doi.org/10.1016/j.ijantimicag.2003.12.019>]
- 17 Tognim MCB, Andrade SS, Silbert D, Gales AC, Jones RN, Sader HS. Resistance trends of *Acinetobacter* spp. In Latin America and characterization of international dissemination of multi-drug resistant strains: five year report of the SENTRY antimicrobial surveillance program. *Int J Infect Dis* 2004;**8**:284-91. [153255 97] [<http://dx.doi.org/10.1016/j.ijid.2003.11.009>]
- 18 Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. *Am J Med* 1993;**94**:281-8. [845 2152] [[http://dx.doi.org/10.1016/002-9343\(93\)90060-3](http://dx.doi.org/10.1016/002-9343(93)90060-3)]
- 19 Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. Epidemiology and impact of imipenem resistance in *Acinetobacter baumannii*. *Infect Control Hosp Epidemiol* 2009;**30**: 1186-92. [19860563] [<http://dx.doi.org/10.1086/648450>]
- 20 Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. *J Clin Pharmacol* 2001;**41**:645-54. [11402633] [<http://dx.doi.org/10.1177/00912700122010537>]
- 21 Lewis JR, Lewis SA. Colistin interactions with mammalian outothelium. *Am J physiol cell physiol* 2004;**286**:C913-22. [14668261] [<http://dx.doi.org/10.1152/ajpcell.00437.2003>]
- 22 Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global Challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2007;**51**:3471-84. [17646423] [<http://dx.doi.org/10.1128/AAC.01464-06>]
- 23 Turton JF, Kaufmann ME, Glover J, Coelho JM, Warner M, Pike R, Pitt TL. Detection and typing of integrons in epidemic strains of *Acinetobacter baumannii* found in the United Kingdom. *J Clin Microbiol* 2005;**43**:3074-82. [16000417] [<http://dx.doi.org/10.1128/JCM.43.7.3074-3082.2005>]
- 24 Gonzalez G, Sossa K, Bello H, Dominguez M, Mella S, Zemelman R. Presence of integrons in isolates of different biotypes of *Acinetobacter baumannii* from Chilean hospitals. *FEMS Microbiol lett* 1998;**161**:125-8. [9561739] [<http://dx.doi.org/10.1111/j.1574-6968.1998.tb12937.x>]
- 25 Seward RJ, Towner KJ. Detection of integrons in worldwide nosocomial isolates of *Acinetobacter* spp. *Clin Microbiol Infect* 1999;**5**:308-318. [11 856275] [<http://dx.doi.org/10.1111/j.1469-0691.1999.tb00149.x>]